10 Most Commonly Asked Questions About Which Antiplatelet Agent to Prescribe
The Neurologist 9:318-322, Adams,H.P. Jr., 2003
Cerebral Sinus Thrombosis Diagnosed by MRI and MR Venography in Cancer Patients
Neurol 54:1222-1226, Raizer,J.J.&DeAngelis,L.M., 2000
Superior Sagittal Sinus Thrombosis
Arch Neurol 34:2, Gettelfinger,D.M.,et al, 1977
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Ischemic Stroke in Cancer Patients: A Review of an Underappreciated Pathology
Ann Neurol 83:873-883, Navi, B.B. & Iadecola, C., 2018
Optimal Timing of Anticoagulant Treatment after Intracerebral Hemorrhage in Patients with Atrial Fibrillation
Stroke 48:314-320, Pennlert, J.,et al, 2017
The Value of Transesophageal Echocardiography for Embolic Strokes of Undetermined Source
Neuol 87:988-995, Katsanos, A.H.,et al, 2016
Antiplatelet Treatment Compared with Anticoagulation Treatment for Cervical Artery Dissection (CADISS): A Randomized Trial
Lancet Neurol 14:361-367, the CADISS Trial investigators, 2015
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Stroke Patients with Suspected Atrial Fibrillation Should be Started on Anticoagulation Pending the Results of Long-Term Cardiac Monitoring
Stroke 44:298-299,302, Diener, H., 2013
Stroke Patients with Suspected Atrial Fibrillation Should NOT be Started on Anticoagulation WHILE AWAITING the Results of Long-Term Cardiac Monitoring
Stroke 44:300-301,302, Katsnelson, M. & Sacco, R., 2013
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data
Pharmacol Ther 129:185-194, Terry, K.W.,et al, 2011
Dabigatran Challenges Warfarins Superiority for Stroke Prevention in Atrial Fibrillation
Stroke 41:1307-1309, Schwartz,N.E. &Albers,G.W., 2010
Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Effect of Home Testing of International Normalized Ratio on Clinical Events
NEJM 363:1608-1620, Matchar,D.B.,et al, 2010
Study Design of the CLOSURE I Trial: A Prospective, Multicenter, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex Septal Closure System Versus Best Medical Therapy in Patients With Stroke or TIA Due to Presumed Paradoxical Embolism Through a PFO
Stroke 41:2872-2883, Furlan,A.J.,et al, 2010
Potentially Preventable Strokes in High-Risk Patients with Atrial Fibrillation Who Are Not Adequately Anticoagulated
Stroke 40:235-240,5, Gladstone,D.J.,et al, 2009
Effect of Age on Stroke Prevention Therapy in Patients with Atrial Fibrillation: The Atrial Fibrillation Investigators
Stroke 40:1410-1416, van Walraven,C.,et al, 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Lateral Sinus Thrombosis: Complication of Minor Head Injury
Int J Pediatr Otorhinolaryngol 73:629-635, Nehme, J.,et al, 2009
Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No History of Stroke or Transient Ischemic Attacks
Stroke 39:1399-1400, Aguilar,M.I. &Hart,R., 2008
Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)
Stroke 39:1482-1486,1406, Healey,J.S.,et al, 2008
Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation
Stroke 39:1901-1910, Stroke Risk in Atrial Fibrillation Working Group, 2008
Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008
Progress in Secondary Stroke Prevention
Ann Neurol 63:418-427, Romano,J.G. &Sacco,R.L., 2008
Treatment of Childhood Arterial Ischemic Stroke
Ann Neurol 63:679-696, Bernard,T.J.,et al, 2008
Cerebral Venous Thrombosis: A Descriptive Multicenter Study of Patients in Pakistan and Middle East
Stroke 39:2707-2711, Khealani,B.,et al, 2008
Secondary Stroke Prevention With Ximelagatran Versus Warfarin in Patients With Atrial Fibrillation: Pooled Analysis of SPORTIF III and V Clinical Trials
Stroke 38:874-880, Akins,P.T.,et al, 2007
Investigating Suspected Cerebral Venous Thrombosis
BMJ 334:794-795, Smit,R. &Hourihan,M.D., 2007
Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
Stroke 38:2459-2463,2409, Baruch,L.,et al, 2007
Therapeutic Strategies After Examination by Transesophageal Echocardiography in 503 Patients with Ischemic Stroke
Stroke 37:859-864, Harloff,A.,et al, 2006
Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Stroke 37:1217-1220, Somerfield,J.,et al, 2006
Immediate Anticoagulation for Acute Stroke in Atrial Fibrillation: Yes
Stroke 37:3052-3053,3056, Chamorro,., 2006
Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients with Nonrheumatic ATrial Fibrillation and a History of Stroke or Transient Ischemic Attack
Stroke 36:914-915, Saxena,R. &Koudstaal,P.J., 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Thrombosis of the Cerebral VEins and Sinuses
NEJM 352:1791-1798, Stam,J., 2005
Cerebral Venous Thrombosis: Influence of Risk Factors and Imaging Findings on Prognosis
Clin Neurol Neurosurg 107:371-378, Appenzeller,S.,et al, 2005
Prescription of Antithrombotic Therapy in Older Patients Hospitalized for Transient Ischemic Attack and Ischemic Stroke:The GIFA Study
Stroke 35:913-917, Volpato,S.,et al, 2004
Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Further Vascular Events After Transient Ischemic Attack or Minor Stroke of Presumed Arterial Origin
Stroke 34:234-235, Algra,A.,et al, 2003
Oral Anticoagulation in Patients After Cerebral Ischemia of Arterial Origin and Risk of Intracranial Hemorrhage
Stroke 34:e45, ESPRIT, 2003
A Risk Score for Predicting Stroke or Death in Individuals with New-Onset Atrial Fibrillation in the Community
JAMA 290:1049-1056,1093, Wang,T.J.,et al, 2003
Stroke Prevention in Atrial Fibrillation
JAMA 290:1093-1095, Waldo,A.L., 2003
A 50-Year-Old Woman With Atrial Fibrillation
JAMA 290:2182-2189, Singer,D.E., 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Emergent Use of Anticoagulation for Treatment of Patients with Ischemic Stroke
Stroke 33:856-861, Adams,H.P., 2002
Warfarin-Aspirin Recurrent Stroke Study (WARSS) Trial
Stroke 33:1723-1726, Hankey,G.J., 2002
Anticoagulants and Antiplatelet Agents in Acute Ischemic Stroke
Neurol 59:13-22, Coull,B.M.,et al, 2002